Heart gene therapy company Tenaya to lay off 30% to 40% of staffnews2025-03-31T19:45:52+00:00March 31st, 2025|Endpoints News|
Vaxcyte’s Phase 2 pneumococcal vaccine data disappoint investorsnews2025-03-31T19:05:15+00:00March 31st, 2025|Endpoints News|
Corcept shares soar after Phase 3 win in ovarian cancernews2025-03-31T16:51:12+00:00March 31st, 2025|Endpoints News|
Merck’s PAH drug slashed risk of serious events in halted trialnews2025-03-31T16:23:43+00:00March 31st, 2025|Endpoints News|
AstraZeneca’s cholesterol pill is set for Phase 3, but lags behind Merck rivalnews2025-03-31T16:00:22+00:00March 31st, 2025|Endpoints News|
Biotech markets fall as industry takes stock of Marks’ exit at FDAnews2025-03-31T15:44:11+00:00March 31st, 2025|Endpoints News|
Lilly’s heart drug study shows potential for once-a-year dosingnews2025-03-31T15:33:00+00:00March 31st, 2025|Endpoints News|
Transcend’s neuroplastogen notches Phase 2 win to treat PTSDnews2025-03-31T11:00:33+00:00March 31st, 2025|Endpoints News|
BiomX’s phage therapy BX211 succeeds in Phase 2 diabetic bone infection studynews2025-03-31T10:30:50+00:00March 31st, 2025|Endpoints News|
Vertex’s second-generation diabetes cell therapy fails early-stage studynews2025-03-31T01:21:19+00:00March 31st, 2025|Endpoints News|
